Literature DB >> 31300268

Reconsideration of the cut-off value of angiotensin-converting enzyme for screening of sarcoidosis in Japanese patients.

Yuichi Baba1, Toru Kubo2, Shigeo Yamanaka3, Yuri Ochi1, Takayoshi Hirota1, Naohito Yamasaki1, Hiroshi Ohnishi4, Tetsuya Kubota4, Akihito Yokoyama4, Hiroaki Kitaoka1.   

Abstract

BACKGROUND: In clinical practice, we frequently experience patients with sarcoidosis who show relatively high but normal values of angiotensin-converting enzyme (ACE). The objective of this study was to reconsider the cut-off value of ACE.
METHODS: We studied 79 Japanese patients who were diagnosed as having sarcoidosis at our hospital. We excluded patients who had taken steroids or ACE inhibitors and patients with renal impairment. We respectively evaluated ACE values and performed receiver operating characteristic (ROC) analysis from a comparison with data for 299 normal Japanese subjects who showed ACE values in the current Japanese standard normal range (7.0-25.0IU/L).
RESULTS: Patients with sarcoidosis had higher ACE values than those in normal subjects (ACE: 20.3IU/L [IQR, 16.0-24.4] vs. 15.4IU/L [IQR, 12.8-18.5]; p<0.001). However, 62 patients (78.5%) had normal ACE levels (cut-off value <25.0IU/L), and the sensitivity of ACE level for detecting sarcoidosis was only 21.5%. From ROC analysis, a cut-off value of 17.7IU/L (AUC: 0.727, 95% CI: 0.660-0.794, p<0.001) was the best cut-off value for detecting sarcoidosis and sensitivity increased to 67.0%.
CONCLUSIONS: The possibility of sarcoidosis cannot be ruled out by using the current Japanese standard value even in patients who have normal ACE levels. Careful interpretation of this biomarker is needed.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Angiotensin-converting enzyme; Cut-off value; Sarcoidosis

Year:  2019        PMID: 31300268     DOI: 10.1016/j.jjcc.2019.05.007

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  Diagnostic and Staging Value of Serum Angiotensin-Converting Enzyme in Sarcoidosis.

Authors:  Wenqiao Wang; Yue Ma; Yongming Zhang; Jiangtao Lin; Jie He; Ying Nong; Xiaoyan Zhang; Yuping Jia
Journal:  Comput Math Methods Med       Date:  2022-02-22       Impact factor: 2.238

2.  Sarcoidosis developing after COVID-19: A case report.

Authors:  Dujrath Somboonviboon; Anan Wattanathum; Narumon Keorochana; Kittisak Wongchansom
Journal:  Respirol Case Rep       Date:  2022-08-11

Review 3.  Sarcoidosis and autoimmunity: In the depth of a complex relationship.

Authors:  Luigi Rizzi; Carlo Sabbà; Patrizia Suppressa
Journal:  Front Med (Lausanne)       Date:  2022-09-06

4.  The critical role of histology in distinguishing sarcoidosis from common variable immunodeficiency disorder (CVID) in a patient with hypogammaglobulinemia.

Authors:  Rohan Ameratunga; Yeri Ahn; Dominic Tse; See-Tarn Woon; Jennifer Pereira; Sinead McCarthy; Hilary Blacklock
Journal:  Allergy Asthma Clin Immunol       Date:  2019-12-02       Impact factor: 3.406

5.  Comprehensive miRNA Analysis Using Serum From Patients With Noninfectious Uveitis.

Authors:  Masaki Asakage; Yoshihiko Usui; Naoya Nezu; Hiroyuki Shimizu; Kinya Tsubota; Naoyuki Yamakawa; Masakatsu Takanashi; Masahiko Kuroda; Hiroshi Goto
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-09-01       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.